Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
W922
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
W922 is a novel small molecule inhibitor of the PI3K/Akt/mTOR signaling pathway. It has demonstrated potent anti-tumor activity in various human cancer cell lines, including colorectal (HCT116), breast (MCF-7), and lung (A549) cancers. In preclinical studies, W922 has been shown to inhibit cell proliferation, induce G0-G1 phase cell cycle arrest, and trigger autophagy by dephosphorylating key proteins in the PI3K/Akt/mTOR axis. Research indicates that combining W922 with autophagy inhibitors like chloroquine can enhance its pro-apoptotic effects, suggesting a potential therapeutic strategy for colorectal cancer.
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on W922.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on W922.